M Felices1, S Chu2, B Kodal2, L Bendzick3, C Ryan3, A J Lenvik2, K L M Boylan4, H C Wong5, A P N Skubitz6, J S Miller2, M A Geller3. 1. Department of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, MN, United States. Electronic address: mfelices@umn.edu. 2. Department of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, MN, United States. 3. Department of Obstetrics, Gynecology and Women's Health, Division of Gynecologic Oncology, University of Minnesota, Minneapolis, MN, United States. 4. Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, United States. 5. Altor BioScience Corporation, Miramar, FL, United States. 6. Department of Obstetrics, Gynecology and Women's Health, Division of Gynecologic Oncology, University of Minnesota, Minneapolis, MN, United States; Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, United States.
Abstract
OBJECTIVE: Natural killer (NK) cells represent a powerful immunotherapeutic target as they lyse tumors directly, do not require differentiation, and can elicit potent inflammatory responses. The objective of these studies was to use an IL-15 super-agonist complex, ALT-803 (Altor BioScience Corporation), to enhance the function of both normal and ovarian cancer patient derived NK cells by increasing cytotoxicity and cytokine production. METHODS: NK cell function from normal donor peripheral blood mononuclear cells (PBMCs) and ovarian cancer patient ascites was assessed using flow cytometry and chromium release assays ±ALT-803 stimulation. To evaluate the ability of ALT-803 to enhance NK cell function in vivo against ovarian cancer, we used a MA148-luc ovarian cancer NOD scid gamma (NSG) xenogeneic mouse model with transferred human NK cells. RESULTS: ALT-803 potently enhanced functionality of NK cells against all ovarian cancer cell lines with significant increases seen in CD107a, IFNγ and TNFα expression depending on target cell line. Function was also rescued in NK cells derived from ovarian cancer patient ascites. Finally, only animals treated with intraperitoneal ALT-803 displayed an NK dependent significant decrease in tumor. CONCLUSIONS: ALT-803 enhances NK cell cytotoxicity against ovarian cancer in vitro and in vivo and is able to rescue functionality of NK cells derived from ovarian cancer patient ascites. These findings suggest that ALT-803 has the potential to enhance NK cell-based immunotherapeutic approaches for the treatment of ovarian cancer.
OBJECTIVE: Natural killer (NK) cells represent a powerful immunotherapeutic target as they lyse tumors directly, do not require differentiation, and can elicit potent inflammatory responses. The objective of these studies was to use an IL-15 super-agonist complex, ALT-803 (Altor BioScience Corporation), to enhance the function of both normal and ovarian cancerpatient derived NK cells by increasing cytotoxicity and cytokine production. METHODS: NK cell function from normal donor peripheral blood mononuclear cells (PBMCs) and ovarian cancerpatientascites was assessed using flow cytometry and chromium release assays ±ALT-803 stimulation. To evaluate the ability of ALT-803 to enhance NK cell function in vivo against ovarian cancer, we used a MA148-luc ovarian cancer NOD scid gamma (NSG) xenogeneic mouse model with transferred human NK cells. RESULTS:ALT-803 potently enhanced functionality of NK cells against all ovarian cancer cell lines with significant increases seen in CD107a, IFNγ and TNFα expression depending on target cell line. Function was also rescued in NK cells derived from ovarian cancerpatientascites. Finally, only animals treated with intraperitoneal ALT-803 displayed an NK dependent significant decrease in tumor. CONCLUSIONS:ALT-803 enhances NK cell cytotoxicity against ovarian cancer in vitro and in vivo and is able to rescue functionality of NK cells derived from ovarian cancerpatientascites. These findings suggest that ALT-803 has the potential to enhance NK cell-based immunotherapeutic approaches for the treatment of ovarian cancer.
Authors: A D Santin; P L Hermonat; A Ravaggi; S Bellone; J J Roman; C V Smith; S Pecorelli; A Radominska-Pandya; M J Cannon; G P Parham Journal: Gynecol Obstet Invest Date: 2001 Impact factor: 2.031
Authors: Bree Foley; Sarah Cooley; Michael R Verneris; Julie Curtsinger; Xianghua Luo; Edmund K Waller; Daniel J Weisdorf; Jeffrey S Miller Journal: Blood Date: 2011-07-14 Impact factor: 22.113
Authors: Manish S Patankar; Yu Jing; Jamie C Morrison; Jennifer A Belisle; Frank A Lattanzio; Yuping Deng; Nyet Kui Wong; Howard R Morris; Anne Dell; Gary F Clark Journal: Gynecol Oncol Date: 2005-08-29 Impact factor: 5.482
Authors: Mathias Krockenberger; Yvonne Dombrowski; Claudia Weidler; Monika Ossadnik; Arnd Hönig; Sebastian Häusler; Heike Voigt; Jürgen C Becker; Lin Leng; Alexander Steinle; Michael Weller; Richard Bucala; Johannes Dietl; Jörg Wischhusen Journal: J Immunol Date: 2008-06-01 Impact factor: 5.422
Authors: Jennifer A Belisle; Jennifer A A Gubbels; Cara A Raphael; Martine Migneault; Claudine Rancourt; Joseph P Connor; Manish S Patankar Journal: Immunology Date: 2007-07-06 Impact factor: 7.397
Authors: Lin Zhang; Jose R Conejo-Garcia; Dionyssios Katsaros; Phyllis A Gimotty; Marco Massobrio; Giorgia Regnani; Antonis Makrigiannakis; Heidi Gray; Katia Schlienger; Michael N Liebman; Stephen C Rubin; George Coukos Journal: N Engl J Med Date: 2003-01-16 Impact factor: 91.245
Authors: Jennifer A A Gubbels; Mildred Felder; Sachi Horibata; Jennifer A Belisle; Arvinder Kapur; Helen Holden; Sarah Petrie; Martine Migneault; Claudine Rancourt; Joseph P Connor; Manish S Patankar Journal: Mol Cancer Date: 2010-01-20 Impact factor: 27.401
Authors: Run Xiao; Anthony G Mansour; Wei Huang; Logan A Chrislip; Ryan K Wilkins; Nicholas J Queen; Youssef Youssef; Hsiaoyin C Mao; Michael A Caligiuri; Lei Cao Journal: Mol Ther Date: 2019-02-16 Impact factor: 11.454
Authors: Locke D Uppendahl; Martin Felices; Laura Bendzick; Caitlin Ryan; Behiye Kodal; Peter Hinderlie; Kristin L M Boylan; Amy P N Skubitz; Jeffrey S Miller; Melissa A Geller Journal: Gynecol Oncol Date: 2019-01-15 Impact factor: 5.482
Authors: Ashley Pinette; Elizabeth McMichael; Nicholas B Courtney; Megan Duggan; Brooke N Benner; Fouad Choueiry; Lianbo Yu; David Abood; Thomas A Mace; William E Carson Journal: Cancer Immunol Immunother Date: 2019-07-23 Impact factor: 6.968
Authors: Annelise Y Mah; Armin Rashidi; Molly P Keppel; Nermina Saucier; Emily K Moore; Joshua B Alinger; Sandeep K Tripathy; Sandeep K Agarwal; Emily K Jeng; Hing C Wong; Jeffrey S Miller; Todd A Fehniger; Emily M Mace; Anthony R French; Megan A Cooper Journal: JCI Insight Date: 2017-12-07